Cambridge Cognition, the UK developer of
neuropsychological tests for the pharmaceutical industry and research
institutions, announced its plans to launch a range of touch-screen mobile
(tablet-based) cognitive assessments for doctors to use with their patients at
every stage of life.
First to market within the next 12 months will be an iPad
GP version of their well-established PAL memory test to aid early detection of
Alzheimer’s disease.
Over the last 25 years, Cambridge Cognition’s
touch-screen cognitive tests, known as CANTAB®, have been cited in over 700
peer-reviewed publications and used around the world in academic research and by
the pharmaceutical and nutraceutical industries in numerous clinical trials and
research.
Now for the first time, CANTAB will also be launched into
mainstream primary care. The test will allow GPs to triage patients presenting
with memory problems quickly, simply and accurately.
Traditionally, memory screening is carried out by GPs
using a pencil and paper test, most commonly the mini mental state exam (MMSE).
The technologies we are developing today and placing on
tablet platforms such as the iPad will enable effective patient identification
and stratification to help target treatments more efficiently not just
pharmaceutical but also lifestyle, nutritional and social care interventions,”
said Andrew Blackwell, CSO.
Our aim is to provide technologies that assist in
patient evaluation for General Practitioners, Family Physicians as well as
clinical specialists. Increasingly, our customers also include military and
educational institutions; and we believe that in future, employers, insurers
and consumers will feature among the groups we serve,” Blackwell added.
By Telecomlead.com Team
editor@telecomlead.com
